Irbepress-Hct (Hydrochlorothiazide, Irbesartan)

Irbepress-Hct is used to manage high blood pressure, a key component of the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: lowers systolic and diastolic pressure, reducing the risk of cardiovascular events.

• Irbesartan selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion, which together reduce peripheral vascular resistance and blood volume, leading to lowered arterial pressure.

Irbepress-Hct may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal upset

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Acute kidney injury or worsening renal function
• Hyperkalemia, especially when combined with potassium‑sparing agents
• Angioedema or severe allergic reaction
• Significant hypotension
• Pancreatitis (rare)

Before prescribing Irbepress-Hct, clinicians should consider several safety factors.

• Renal function: monitor serum creatinine and eGFR regularly.
• Electrolytes: check potassium and sodium levels, especially in the first weeks.
• Concomitant diuretics: adjust dose to avoid excessive volume depletion.
• Pregnancy: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Sulfonamide allergy: avoid in patients with known hypersensitivity to sulfonamide structures.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbepress-Hct can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Aliskiren combined with an ARB in diabetic patients: risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Lithium: increased lithium levels and toxicity.
• ACE inhibitors or other ARBs: additive effects on blood pressure and potassium.
• NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives (beta‑blockers, calcium channel blockers): may require dose adjustments to prevent hypotension.
• CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma concentrations.
• Antidiabetic agents: monitor blood glucose as blood pressure changes can affect glycemic control.